Inhibition of triple‑negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt

Cao,Wei; Shen,Renhui; Richard,Seth; Liu,Yu; Jalalirad,Mohammad; Cleary,Margot P.; D'Assoro,Antonio B.; Gradilone,Sergio A.; Yang,Da-Qing

doi:10.3892/or.2021.8252

Inhibition of triple‑negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt

Authors:
- Wei Cao
- Renhui Shen
- Seth Richard
- Yu Liu
- Mohammad Jalalirad
- Margot P. Cleary
- Antonio B. D'Assoro
- Sergio A. Gradilone
- Da-Qing Yang
View Affiliations

Affiliations: The Hormel Institute, University of Minnesota, Austin, MN 55912, USA, Sir Run Run Shaw Hospital, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China, Mayo Clinic, Rochester, MN 55905, USA
Published online on: December 24, 2021 https://doi.org/10.3892/or.2021.8252
Article Number: 41

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mutations of p53 tumor suppressors occur more frequently in cancers at advanced stages or in more malignant cancer subtypes such as triple‑negative breast cancer. Thus, restoration of p53 tumor suppressor function constitutes a valuable cancer therapeutic strategy. In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY‑1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21. These results suggested that ACY‑1215 may lead to enhanced transcriptional activity of p53. It was also determined that ACY‑1215 treatment resulted in G1 cell cycle arrest and apoptosis in these cancer cells. Furthermore, ACY‑1215 displayed a synergistic effect with specific inhibitors of ATM, an activator of Akt, in inducing cancer cell apoptosis and inhibiting their motility. More importantly, it was observed that combination of ACY‑1215 and ATM inhibitors exhibited markedly more potent antitumor activity than the individual compound in xenograft mouse models of breast cancer with mutant p53. Collectively, our results demonstrated that ACY‑1215 is a novel chemotherapeutic agent that could restore mutant p53 function in cancer cells with strong antitumor activity, either alone or in combination with inhibitors of the ATM protein kinase.

View Figures

View References

1	Halaby MJ and Yang DQ: p53 translational control: A new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene. 395:1–7. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ji B, Harris BR, Liu Y, Deng Y, Gradilone SA, Cleary MP, Liu J and Yang DQ: Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics. Int J Mol Sci. 18:932017. View Article : Google Scholar : PubMed/NCBI
3	Network TCGA; Cancer Genome Atlas Network, : Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
4	Brown CJ, Cheok CF, Verma CS and Lane DP: Reactivation of p53: From peptides to small molecules. Trends Pharmacol Sci. 32:53–62. 2011. View Article : Google Scholar : PubMed/NCBI
5	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
6	Ryu HW, Shin DH, Lee DH, Choi J, Han G, Lee KY and Kwon SH: HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis. Cancer Lett. 391:162–171. 2017. View Article : Google Scholar : PubMed/NCBI
7	Seidel C, Schnekenburger M, Dicato M and Diederich M: Histone deacetylase 6 in health and disease. Epigenomics. 7:103–118. 2015. View Article : Google Scholar : PubMed/NCBI
8	Lorenzo Pisarello M, Masyuk TV, Gradilone SA, Masyuk AI, Ding JF, Lee PY and LaRusso NF: Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. Am J Pathol. 188:981–994. 2018. View Article : Google Scholar : PubMed/NCBI
9	Li Y and Yang DQ: The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol Cancer Ther. 9:113–125. 2010. View Article : Google Scholar : PubMed/NCBI
10	Halaby MJ, Hibma JC, He J and Yang DQ: ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell Signal. 20:1555–1563. 2008. View Article : Google Scholar : PubMed/NCBI
11	Halaby MJ, Kastein BK and Yang DQ: Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells through activation of Akt. Biochem Biophys Res Commun. 435:708–713. 2013. View Article : Google Scholar : PubMed/NCBI
12	Harris BRE, Zhang Y, Tao J, Shen R, Zhao X, Cleary MP, Wang T and Yang DQ: ATM inhibitor KU-55933 induces apoptosis and inhibits motility by blocking GLUT1-mediated glucose uptake in aggressive cancer cells with sustained activation of Akt. FASEB J. 35:e212642021. View Article : Google Scholar : PubMed/NCBI
13	Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, et al: Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 8:2894–2902. 2009. View Article : Google Scholar : PubMed/NCBI
14	Jänicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:9357–9360. 1998. View Article : Google Scholar : PubMed/NCBI
15	Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ and Thor AD: Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 61:348–354. 2001.PubMed/NCBI
16	Zhang B, Shetti D, Fan C and Wei K: miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3. Biol Res. 52:382019. View Article : Google Scholar : PubMed/NCBI
17	Iorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, El Ashry D and Lippman M: A new mouse model for the study of human breast cancer metastasis. PLoS One. 7:e479952012. View Article : Google Scholar : PubMed/NCBI
18	Halaby MJ, Harris BR, Miskimins WK, Cleary MP and Yang DQ: Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage. Mol Cell Biol. 35:4006–4017. 2015. View Article : Google Scholar : PubMed/NCBI
19	Harris BRE, Wang D, Zhang Y, Ferrari M, Okon A, Cleary MP, Wagner CR and Yang DQ: Induction of the p53 Tumor Suppressor in Cancer Cells through Inhibition of Cap-Dependent Translation. Mol Cell Biol. 38:382018. View Article : Google Scholar : PubMed/NCBI
20	D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, Busby R, Whitehead C, Stivala F, Lingle WL and Salisbury JL: Amplified centrosomes in breast cancer: A potential indicator of tumor aggressiveness. Breast Cancer Res Treat. 75:25–34. 2002. View Article : Google Scholar : PubMed/NCBI
21	D'Assoro AB, Busby R, Suino K, Delva E, Almodovar-Mercado GJ, Johnson H, Folk C, Farrugia DJ, Vasile V, Stivala F, et al: Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene. 23:4068–4075. 2004. View Article : Google Scholar : PubMed/NCBI
22	D'Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Farrugia DJ, Schroeder MA, Allen C, Stivala F, Galanis E, et al: Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 ×enografts. Oncogene. 27:3901–3911. 2008. View Article : Google Scholar : PubMed/NCBI
23	DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008. View Article : Google Scholar : PubMed/NCBI
24	Chen JQ and Russo J: Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim Biophys Acta. 1826:370–384. 2012.PubMed/NCBI
25	Barron CC, Bilan PJ, Tsakiridis T and Tsiani E: Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 65:124–139. 2016. View Article : Google Scholar : PubMed/NCBI